Wells Fargo’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $30.5M | Sell |
231,311
-10,800
| -4% | -$1.43M | 0.01% | 1244 |
|
|
2025
Q4 | $34.3M | Sell |
242,111
-16,235
| -6% | -$2.35M | 0.01% | 1154 |
|
|
2025
Q3 | $36.3M | Sell |
258,346
-25,992
| -9% | -$3.52M | 0.01% | 1102 |
|
|
2025
Q2 | $35.7M | Buy |
284,338
+28,947
| +11% | +$3.32M | 0.01% | 1037 |
|
|
2025
Q1 | $28.2M | Buy |
255,391
+8,812
| +4% | +$1.12M | 0.01% | 1109 |
|
|
2024
Q4 | $33.7M | Sell |
246,579
-13,836
| -5% | -$1.71M | 0.01% | 1017 |
|
|
2024
Q3 | $30M | Buy |
260,415
+25,446
| +11% | +$3.49M | 0.01% | 1054 |
|
|
2024
Q2 | $32.3M | Buy |
234,969
+13,155
| +6% | +$1.8M | 0.01% | 950 |
|
|
2024
Q1 | $30.6M | Buy |
221,814
+118,786
| +115% | +$16.2M | 0.01% | 983 |
|
|
2023
Q4 | $13.6M | Sell |
103,028
-4,493
| -4% | -$517K | ﹤0.01% | 1446 |
|
|
2023
Q3 | $12.1M | Buy |
107,521
+4,748
| +5% | +$500K | ﹤0.01% | 1425 |
|
|
2023
Q2 | $9.69M | Buy |
102,773
+11,559
| +13% | +$1.13M | ﹤0.01% | 1621 |
|
|
2023
Q1 | $9.23M | Buy |
91,214
+969
| +1% | +$101K | ﹤0.01% | 1659 |
|
|
2022
Q4 | $10.8M | Buy |
90,245
+2,500
| +3% | +$293K | ﹤0.01% | 1494 |
|
|
2022
Q3 | $9.32M | Sell |
87,745
-2,334
| -3% | -$237K | ﹤0.01% | 1571 |
|
|
2022
Q2 | $8.78M | Sell |
90,079
-13,684
| -13% | -$1.26M | ﹤0.01% | 1657 |
|
|
2022
Q1 | $9.73M | Buy |
103,763
+11,495
| +12% | +$974K | ﹤0.01% | 1861 |
|
|
2021
Q4 | $7.86M | Sell |
92,268
-199,713
| -68% | -$18.4M | ﹤0.01% | 2082 |
|
|
2021
Q3 | $28M | Sell |
291,981
-82,475
| -22% | -$7.79M | 0.01% | 1421 |
|
|
2021
Q2 | $36.4M | Buy |
374,456
+70,615
| +23% | +$6.77M | 0.01% | 1273 |
|
|
2021
Q1 | $29.5M | Sell |
303,841
-21,408
| -7% | -$2.24M | 0.01% | 1369 |
|
|
2020
Q4 | $31.2M | Buy |
325,249
+21,837
| +7% | +$2.11M | 0.01% | 1264 |
|
|
2020
Q3 | $29.2M | Buy |
303,412
+22,387
| +8% | +$2.59M | 0.01% | 1165 |
|
|
2020
Q2 | $34.3M | Buy |
281,025
+38,758
| +16% | +$4.28M | 0.01% | 1051 |
|
|
2020
Q1 | $21M | Buy |
242,267
+19,579
| +9% | +$1.92M | 0.01% | 1209 |
|
|
2019
Q4 | $23.9M | Buy |
222,688
+7,041
| +3% | +$737K | 0.01% | 1354 |
|
|
2019
Q3 | $19.4M | Sell |
215,647
-19,910
| -8% | -$1.86M | 0.01% | 1459 |
|
|
2019
Q2 | $19.9M | Sell |
235,557
-321,079
| -58% | -$26.4M | 0.01% | 1476 |
|
|
2019
Q1 | $49M | Sell |
556,636
-152,179
| -21% | -$12.7M | 0.01% | 902 |
|
|
2018
Q4 | $50.6M | Sell |
708,815
-326,254
| -32% | -$31.3M | 0.02% | 816 |
|
|
2018
Q3 | $127M | Sell |
1,035,069
-24,977
| -2% | -$2.83M | 0.04% | 496 |
|
|
2018
Q2 | $104M | Buy |
1,060,046
+104,738
| +11% | +$9.38M | 0.03% | 559 |
|
|
2018
Q1 | $79.2M | Sell |
955,308
-10,141
| -1% | -$856K | 0.02% | 673 |
|
|
2017
Q4 | $74.9M | Buy |
965,449
+20,081
| +2% | +$1.37M | 0.02% | 703 |
|
|
2017
Q3 | $57.9M | Buy |
945,368
+119,383
| +14% | +$6.3M | 0.02% | 797 |
|
|
2017
Q2 | $38M | Buy |
825,985
+528,863
| +178% | +$25.7M | 0.01% | 1005 |
|
|
2017
Q1 | $12.9M | Buy |
297,122
+175,292
| +144% | +$7.51M | ﹤0.01% | 1704 |
|
|
2016
Q4 | $4.71M | Buy |
121,830
+63,931
| +110% | +$2.89M | ﹤0.01% | 2456 |
|
|
2016
Q3 | $2.93M | Buy |
57,899
+7,792
| +16% | +$388K | ﹤0.01% | 2672 |
|
|
2016
Q2 | $2.28M | Sell |
50,107
-18,487
| -27% | -$851K | ﹤0.01% | 2878 |
|
|
2016
Q1 | $2.71M | Sell |
68,594
-11,106
| -14% | -$441K | ﹤0.01% | 2705 |
|
|
2015
Q4 | $4.51M | Sell |
79,700
-6,139
| -7% | -$312K | ﹤0.01% | 2403 |
|
|
2015
Q3 | $3.42M | Sell |
85,839
-23,552
| -22% | -$1.14M | ﹤0.01% | 2589 |
|
|
2015
Q2 | $5.22M | Buy |
109,391
+8,771
| +9% | +$372K | ﹤0.01% | 2385 |
|
|
2015
Q1 | $4M | Buy |
100,620
+19,257
| +24% | +$689K | ﹤0.01% | 2543 |
|
|
2014
Q4 | $1.82M | Sell |
81,363
-16,963
| -17% | -$321K | ﹤0.01% | 3076 |
|
|
2014
Q3 | $1.54M | Buy |
98,326
+13,589
| +16% | +$203K | ﹤0.01% | 3166 |
|
|
2014
Q2 | $1.26M | Buy |
84,737
+13,428
| +19% | +$189K | ﹤0.01% | 3363 |
|
|
2014
Q1 | $1.15M | Buy |
71,309
+71,208
| +70,503% | +$1.22M | ﹤0.01% | 3403 |
|
|
2013
Q4 | $1K | Hold |
101
| – | – | ﹤0.01% | 5625 |
|
|
2013
Q3 | $1K | Sell |
101
-1,000
| -91% | -$13.7K | ﹤0.01% | 5531 |
|
|
2013
Q2 | $15K | Buy |
+1,101
| New | +$13.5K | ﹤0.01% | 4955 |
|
Other funds holding NBIX
VPM
VCM
Wells Fargo's NBIX Position: Q1 2026 in Review
Wells Fargo reduced its Neurocrine Biosciences (NBIX) stake by 4.5% in Q1 2026, selling an estimated $1.43M and leaving 231,311 shares worth $30.5M. The position accounts for 0.01% of the portfolio, ranked #1244.
Wells Fargo first reported a position in NBIX in Q2 2013 and has held it in 52 quarters since. The position peaked at $127M in Q3 2018. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Wells Fargo held 231,311 shares of Neurocrine Biosciences worth $30.5M as of Q1 2026.
- Wells Fargo sold 10,800 Neurocrine Biosciences shares in Q1 2026, an estimated $1.43M.
- Neurocrine Biosciences made up 0.01% of Wells Fargo's portfolio in Q1 2026, its #1244 holding.
- Wells Fargo first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 52 quarters since.
- Wells Fargo's Neurocrine Biosciences position peaked at $127M in Q3 2018.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.